New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 3, 2014
09:26 EDTTEVATeva to acquire Labrys Biologics for $200M upfront, up to $625M additionally
Teva Pharmaceutical and Labrys Biologics, a privately-held development stage biotechnology company focused on treatments for chronic migraine and episodic migraine, announced that Teva has entered into a definitive agreement to acquire Labrys for $200M in upfront payment in cash at closing as well as up to $625M in contingent payments upon achievement of certain pre-launch milestones. Labrys is developing LBR-101, a fully humanized monoclonal antibody that binds to calcitonin gene-related peptide currently in Phase IIb clinical trials for prevention of chronic and episodic migraine. Teva’s acquisition of the LBR-101 program targeting high frequency episodic and chronic migraine complements the recent addition of Zecuity, a therapy for the acute treatment of migraine, obtained through the acquisition of NuPathe, Teva said. Potential peak sales for LBR-101 are estimated to reach $2B-$3B, the companies said.
News For TEVA From The Last 14 Days
Check below for free stories on TEVA the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 17, 2014
11:01 EDTTEVAActavis drops after NY AG seeks to block Alzheimer drug switch
Subscribe for More Information
08:05 EDTTEVAEagle Pharm says Teva requests motion to dismiss Bendamustine lawsuit
Subscribe for More Information
September 12, 2014
09:01 EDTTEVATeva to present Copaxone gene expression analysis
Subscribe for More Information
08:06 EDTTEVATeva presents new clinical safety data in RRMS patients treated with Laquinimod
Teva (TEVA) and Active Biotech (ACTI) announced new follow-up data evaluating the clinical safety of laquinimod in patients with relapsing-remitting multiple sclerosis, or RRMS, who were treated with laquinimod in Phase II, Phase III and open-label extension studies for two or more years. The pooled safety analysis of the Phase II LAQ/5063 and the Phase III ALLEGRO and BRAVO extension studies supports findings observed in the core studies where currently identified risks were observed within the first months of laquinimod treatment. In the pooled safety analysis, rates of adverse events, or AEs, and serious AEs were lower in the open-label extensions than in the core studies and less than three percent of patients discontinued treatment due to AEs during these extensions. Additionally, shifts to potentially significant laboratory values were considerably lower in patients exposed to at least two years of laquinimod.
08:03 EDTTEVATeva, Active Biotech present laquinimod follow-up data
Subscribe for More Information
September 11, 2014
09:31 EDTTEVATeva announces new data from Phase IIIb GLACIER study
Subscribe for More Information
03:27 EDTTEVATeva Canada announces launch of generic version of Cipralex
Subscribe for More Information
September 10, 2014
14:25 EDTTEVATeva Canada announces launch of generic version of Cipralex
Subscribe for More Information
September 8, 2014
12:40 EDTTEVAFTC sues AbbVie over blocking of AndroGel generics
The Federal Trade Commission has filed a complaint in federal district court charging several pharmaceutical companies with "illegally blocking American consumers’ access to lower-cost versions of the blockbuster drug AndroGel." The FTC's complaint alleges that AbbVie (ABBV) and its partner Besins Healthcare filed baseless patent infringement lawsuits against potential generic competitors to delay the introduction of lower-priced versions of the testosterone replacement drug AndroGel. While the lawsuits were pending, AbbVie then entered into an anticompetitive pay-for-delay settlement agreement with Teva Pharmaceuticals (TEVA) to further delay generic drug competition, the FTC claims. Reference Link
09:27 EDTTEVALeerink biotech analyst holds a luncheon meeting with a conference call
Biotech Analyst Schwartz provides an update on key trends and controversies for marketed MS therapies and discusses new data presented at ACTRIMS-ECTRIMS at a Luncheon Meeting with an Analyst/Industry conference call to be held in Boston on September 11 at 12:15 pm.
08:02 EDTTEVATeva completes Reslizumab Phase III program
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use